Most Recent
Two law firms that filed competing shareholder class actions against construction giant Boral have asked the court to permanently stay the other's proceeding, after the judge overseeing the matter said he might wait until the High Court's ruling on the AMP class action beauty parade before deciding which class action should move forward.
Global animal health company Zoetis has told the lead applicants in a class action over horse vaccines to "put up or shut up" and produce evidence disclosing an alleged scientific link between the hendra virus vaccine and certain alleged adverse side effects.
A Qantas engineer who used his company-issued iPad to access pornographic material while at work has lost his unfair dismissal case.
The lead applicants in a class action against The Cosmetic Institute have added 11 cosmetic surgeons to the lawsuit, alleging they conducted breast augmentation surgery in an "incompetent" manner.
A referee has been appointed to examine the fees for the liquidators of stockbroker Halifax Investment Services, which collapsed in December 2018, trapping around $200 million in client funds.
National law firm Lander & Rogers has failed in its bid to stop a client reviewing invoices totalling $2 million, even though the legal fees were paid by a litigation funder.
Former Liberal leader John Hewson has filed a defamation suit against Nine, claiming a report by A Current Affair about his insurance firm was gratuitous and "seriously dishonest".
Maddens has once again been criticised for its non-compliant costs agreements, three months after receiving similar feedback from a Victoria Supreme Court judge overseeing the firm's bushfire class actions.
Court documents sought to be kept confidential in a case alleging professional misconduct against barrister Norman O'Bryan SC in his role as counsel for a class action over the collapse of Banksia Securities accuse the top silk of continuing to have an interest in the funder that bankrolled the proceedings after his wife was said to have sold her shares.
Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding the primary judge had erred by ruling that proof of intention was required for Swiss-style claims.